Resume
  • Jan 2019 - Now
    myNEO Therapeutics
    Chief Scientific Officer 2025 - Now
    Chief Technology Officer 2020 - 2024
    Senior Bioinformatician 2019 - 2019

    myNEO Therapeutics is a data-driven biotech company pioneering breakthrough immunotherapies in the fight against cancer. Present from the inception of the company, I led its team of scientists in developing solutions for the optimized detection and prioritization of clinically actionable antigens. Our approach delivered several product formulations, both off-the-shelf and personalized, that are now being taken to the clinic.

    Key achievements:

    • Built ML algorithms enabling the optimized discovery and prioritization of tumor-derived antigens. In controlled, unbiased benchmarks, our models outperformed current state-of-the-art clinical options, and in one case, even broke new ground into better immunogenicity prediction.

    • Developed a cloud-based neoantigen discovery and prioritization pipeline from the ground up. Established good practices for development and deployment, optimized cloud infrastructure according to a cost-based approach, and ensured compliance to GDPR and ISO norms

    • Led discovery efforts to identify actionable off-the-shelf antigen combinations in various cancer indications, leveraging both the canonical and dark genome of the tumour. One of these solutions is currently being tested in a phase I, while one other is currently undergoing pre-clinical validation before the clinic.

    • Secured multiple collaborations with academics, industrials, and hospitals, both in Europe and the US

  • Jan 2017 - Dec 2019
    Data science and bioIT consultant
    Self-employed

    Supported academics and industrials in data analysis or in the development of analysis toolsuites.

    Key achievements:

    • Led the large-scale data analysis for several high-profile papers (RNAseq, WGS, ChIPseq, exosome sequencing)
    • Built differential expression analysis tools to be used by wet lab scientists
  • Jan 2015 - Dec 2017
    University of Pennsylvania, Pierce lab
    Post-doctoral position

    Explored the importance and clinical actionability of epigenetics in cocaine addiction.

    Key achievements:

    • Led a small team in building histone post-translational modification, DNA methylation, and ATAC-seq analysis pipelines from the ground up, all of which were published in high-impact papers
    • Built CRISPR-Cas construct design pipeline for handover to wet lab team
Education
  • University of Nice Sophia Antipolis - PhD - Molecular genetics (2011 - 2015)

    Doctoral research in Molecular Genetics with a heavy tint of Developmental Biology. My thesis is called “Importance du contexte cellulaire et de la régulation spatio-temporelle de l’expression du facteur de transcription Otx2 dans la modulation de ses fonctions”, but please don’t go read it. Our lab was focused on the various roles of the gene OTX2. Otx2 is a fascinating, fascinating gene because it belongs in kind of the same family as the Hox genes; it’s a transcription factor whose function is dramatically important during development (it literally makes sure you have a head), and also reappears later on in life with similarly important (although more bodily restricted) roles in the retina and in the brian in particular.

    Trying to tease out its various functions is exactly what large-scale analyses were made for, and therefore that’s what we used ! We setup a ChIP-seq and interactome model in the adult retina to investigate how exactly Otx2 accomplishes its function. I’ll copy-paste from myself and say that cross-referencing ChIP-seq and interactome data, we showed that while Otx2 shares many binding sites with its homologue Crx, it forms completely different protein complexes, indicating different functional profiles for the various members of the Otx family.

    My favorite part of this thesis, however, is the one I didn’t get time to publish at the time, and will probably never see published ever by now. It dealt with the notions of heterochrony and neoteny as outlined by Stephen Jay Gould n his 1977 book Ontogeny and Phylogeny. Essentially, genes such as Otx2 pop up at some point of embryonic development, do their thing for a little while, and disappear, leaving you with a new limb, a new head, a new torso - they’re that powerful. So… What would happen if any of them happened to be expressed just that little longer ? Would you get an extra limb ? Two torsos ? A bigger head ? Dr Gould says yes to the last one. We wanted to check if that was true in at least some way. We developed a nifty inducible system where you could turn Otx2 on and off on command and tried to play with its time window of expression. The system took forever to set up, was very imperfect, and yielded completely unexpected results - taken together, this produced an article that I still love to this day, but didn’t make it through reviews in time before I graduated, and is still floating in limbo ever since.

    My mentor was Thomas Lamonerie, who taught me both that intellectual curiosity should apply above all else to any question, as well as how to trim down experiments and reasonings to their leanest core.

  • Ecole Normale Superieure de Lyon - Master's degree - Biosciences (2008 - 2010)

    Master’s studies in biosciences at one of France’s top research and teaching institutions. Extensive training in:

    • Molecular Biology
    • Genetics (Molecular Genetics and Population Genetics)
    • Epigenetics
    • Developmental Biology (animal and vegetal, as well as evo-devo)
    • Ecology

    I was lucky enough to benefit from the structure of the Masters then, where multiple internship periods were offered, giving you the chane to explore aspects of biology you wouldn’t necessarily be able to make the time for otherwise. As such, I was able to help evaluating the link between sleep and hippocampus function by setting up a classic memory swim test for rats in a new lab. I also modeled the link between food abundance and the reproductive success of the Great Owled Horn as a model for conservation strategies. Fun fact, the only EU-subsidized conservation strategy for raptors was to release rabbits in the territory of threatened species. The reasoning was to give the raptors easy food so they can stop worrying about it and spend more time reproducing, or at least live longer. Well, we showed that’s not the case. Raptors generally have a close to 100% kill rate, so will pretty much do great regardless unless their prey is endangered itself. Which rabbits are not.

    I used my training gathered here during the other Master in a final internship modeling axin flows in A. thaliana meristem in the Laboratoire Reproduction et Developpement des Plantes. It wasn’t a great success, and the model that I built was horribly inefficient, but it worked, and it was my first foray into the use of data and models in Biology. I learned a lot under the direction of Olivier Hamant and Pradeep Das, and through interactions with my friend Benoit Landrein who did his Masters with me there, got his PhD there, and is now having a brilliant carrer there.

  • Ecole Normale Superieure de Lyon - Master's degree - Complex systems (2008 - 2010)

    Master’s studies in complex systems at one of France’s top research institutions. This was a time where Data Science was not really something thought of in biology - The first sequenced genome was sequenced 5 years earlier, microarray itself was still a kinda new thing… So it was hard to find specific training on applying big data techniques to biology. Inasmuch as people almost don’t use it anymore these days, I don’t even think the term “big data” existed yet then. So when I started looking at opportunities to extend my knowledge in the domain, this (at the time) brand new Master appeared as an evidence.

    It was all built around the idea of modeling and of extracting meaningful information from very complex systems, be they complex by their number of rules or the immense of data they generate, or both. Topics included:

    • Emergent behavior and single-agent modeling
    • Error propagation
    • Differential equations, especially their chaotic behavior
    • Constraint graph models
    • Probabilistic modeling

    I feel incredibly lucky to have been able to follow this course, as I learned so much in it when it comes to way to approach a complex, data-heavy question.

Skills
  • Programming Languages
    • Python
      • overwhelmingly my favorite language. Unoriginal, I know, but I like the modularity, the accessibility, and most of all the ecosystem
    • R
      • because I don’t think there exists a bioinformatician without R knowledge. It also remains superior to most (if not all) alternatives for the visual display of information. I haven’t tried Julia yet though, it also looks interesting.
    • Bash/Shell scripting
      • because regardless of what people think, awk is a programming language - and because you cannot do devops without it
    • SQL
      • because I needed to store things once
    • Front-end programming - Astro/CSS, and a little bit of Javascript
      • you are looking at the extent of my experience with front-end programming
    • perl
      • please don’t make me
  • Bioinformatics
    • Next-generation sequencing (NGS) analyses. I have already used the following NGS-based strategies in the course of my work:
      • NGS-based variant detection (SNVs, indels, CNVs, gene fusions, neoisoforms, transposable elements…)
      • bulk RNAseq
      • scRNAseq
      • GWAS
      • ChIP-seq
      • Exosome sequencing
      • ctDNA sequencing
      • long-read sequencing
      • bisulfite sequencing
    • Proteomics approaches
      • Proteomics
      • Ligandomics, in particular immunopeptidomics
      • Interactomics
    • Pipeline automation and streamlining
    • Reasoned infrastructure in local, HPC, or cloud-based setups
    • Monitoring, compliance, documentation
    • Handover
      • I truly believe this is often a heavily disregarded yet crucial part of any bioinformatics approach. Who’s going to run your tool when you’re gone ?
  • Data Science and Machine Learning
    • Data collection and curation; feature extraction
    • Model building and benchmarking, hyperparameter tuning and monitoring
    • Production-ready packaging
    • Deployment as local tools, distributed ones, or cloud-based, serverless ones
    • Post-production monitoring
  • Team Management

    Establishing deliverables, estimating timelines, follow-up and monitoring, results and insights presentation

Publications
  • 2025
    Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification
    Lena Pfitzer, Gitta Boons, Lien Lybaert, Wim van Criekinge, Cedric Bogaert, Bruno Fant
    Vaccines, 13(8), 865
  • 2024
    Methods behind neoantigen prediction for personalized anticancer vaccines
    Kiyana Godazandeh, Lies Van Olmen, Lore Van Oudenhove, Steve Lefever, Cedric Bogaert, Bruno Fant
    Methods in Cell Biology, 183, 161-186
  • 2023
    Challenges in neoantigen-directed therapeutics
    Lien Lybaert, Steve Lefever, Bruno Fant, Evelien Smits, Bruno De Geest, Karine Breckpot, Luc Dirix, Steven A. Feldman, Wim van Criekinge, Kris Thielemans, Sjoerd H. van der Burg, Patrick A. Ott, Cedric Bogaert
    Cancer Cell, 41(1), 15-40
  • 2022
    Cocaine-Induced Changes in Sperm Cdkn1a Methylation Are Associated with Cocaine Resistance in Male Offspring
    Sarah E. Swinford-Jackson, Bruno Fant, Mathieu E. Wimmer, Donovan Chan, Melissa C. Knouse, Mateo Sarmiento, Arthur S. Thomas, Phillip J. Huffman, Sharvari Mankame, Samantha J. Worobey, R. Christopher Pierce
    Journal of Neuroscience, 42(14), 2905-2916
  • 2022
    Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model
    Lena Pfitzer, Lien Lybaert, Cedric Bogaert, Bruno Fant
    bioRxiv
  • 2022
    neoMS: Attention-based prediction of MHC-I epitope presentation
    Nil Adell Mill, Cedric Bogaert, Wim van Criekinge, Bruno Fant
    bioRxiv
  • 2022
    A synthetic DNA template for fast manufacturing of versatile single epitope mRNA
    Wout de Mey, Phaedra De Schrijver, Dorien Autaers, Lena Pfitzer, Bruno Fant, Hanne Locy, Arthur Esprit, Lien Lybaert, Cedric Bogaert, Magali Verdonck, Kris Thielemans, Karine Breckpot, Lorenzo Franceschini
    Molecular Therapy: Nucleic Acids, 29, 943-954
  • 2021
    Novel algorithm discovers up to 35% more epitopes translated from non-coding regions in cold tumours
    Lena Pfitzer, Lore Van Oudenhove, Cedric Bogaert, Bruno Fant
    Molecular Cancer Therapeutics, 20(12 Suppl), CC01-02
  • 2021
    Novel machine-learning tools improve cost-effective development of personalised immunotherapies: Lowering false positive rates in the search for actionable (personalised and largely shared) immunogenic neoantigens
    Cedric Bogaert, Lena Pfitzer, Nil Adell Mill, Bruno Fant
    Molecular Cancer Therapeutics, 20(12 Suppl), P006
  • 2019
    H3.3 Barcoding of Nucleus Accumbens Transcriptional Activity Identifies Novel Molecular Cascades Associated with Cocaine Self-administration in Mice
    Mathieu E. Wimmer, Bruno Fant, Sarah E. Swinford-Jackson, Alexander Testino, Duncan Van Nest, Ted Abel, R. Christopher Pierce
    Journal of Neuroscience, 39(27), 5247-5254
  • 2019
    Preconception maternal cocaine self-administration increases the reinforcing efficacy of cocaine in male offspring
    Bruno Fant, Mathieu E Wimmer, Sarah E Swinford-Jackson, John Maurer, Duncan Van Nest, R Christopher Pierce
    Psychopharmacology, 236(12), 3429-3437
  • 2019
    Novel biomarkers to assess in utero effects of maternal opioid use: First steps toward understanding short- and long-term neurodevelopmental sequelae
    Laura Goetzl, Tara Thompson-Felix, Nune Darbinian, Nana Merabova, Salim Merali, Carmen Merali, Kathryne Sanserino, Tamara Tatevosian, Bruno Fant, Mathieu E Wimmer
    Genes Brain and Behavior, 18(6), e12583
  • 2018
    Environmental, genetic and epigenetic contributions to cocaine addiction
    R Christopher Pierce, Bruno Fant, Sarah E Swinford-Jackson, Elizabeth A Heller, Wade H Berrettini, Mathieu E Wimmer
    Neuropsychopharmacology, 43(7), 1471-1480
  • 2018
    Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses
    Florian Douam, Carly G K Ziegler, Gabriela Hrebikova, Bruno Fant, Robert Leach, Lance Parsons, Wei Wang, Jenna M Gaska, Benjamin Y Winer, Brigitte Heller, Alex K Shalek, Alexander Ploss
    Nature Communications, 9(1), 5031
  • 2017
    Paternal cocaine taking elicits epigenetic remodeling and memory deficits in male progeny
    M E Wimmer, L A Briand, B Fant, L A Guercio, A C Arreola, H D Schmidt, S Sidoli, Y Han, B A Garcia, R C Pierce
    Molecular Psychiatry, 22(11), 1641-1650
  • 2015
    Comprehensive interactome of Otx2 in the adult mouse neural retina
    Bruno Fant, Alexander Samuel, Stéphane Audebert, Agnès Couzon, Salsabiel El Nagar, Nathalie Billon, Thomas Lamonerie
    Genesis, 53(11), 685-694
  • 2014
    Otx2 ChIP-seq reveals unique and redundant functions in the mature mouse retina
    Alexander Samuel, Michael Housset, Bruno Fant, Thomas Lamonerie
    PLoS One, 9(2), e89110
Patents
  • filed
    Novel polypeptides for the treatment, prevention, and diagnosis of cancer, particularly colorectal cancer
    EP23195733.3
  • granted
    Multi-epitope construct (COVID-19)
    112116809 (Taiwan)
  • granted
    Method, system and computer program product for determining presentation likelihoods of neoantigens
    EP20185779.4 | US2023/0298692
  • granted
    Method, system and computer program product for determining peptide immunogenicity
    EP21791393.8 | US18/031139
Grants, funding, partnerships secured
  • 2025 - secured
    University of Liverpool
    Partnership deal for identification of epitopes in a personalized trial
    €225k
  • 2023 - secured
    Curevac
    Licensing deal for select epitopes in two cancer indications
    €800k secured, €2.4M pending on milestones
  • 2022 - secured
    Hookipa
    Clinical analysis efforts in a HPV off-the-shelf cancer vaccine
    €550k
  • 2021 - pending
    Odimma
    Partnership deal for identification of epitopes in a personalized trial
    €1.5M
  • 2020 - secured
    eTheRNA
    Discovery and vaccine design for a COVID-19 vaccine
    €150k
  • 2019 - secured
    Immunopepx VLAIO grant
    Exploring the neoantigen landscape of colorectal cancer
    €1.5M
  • 2015 - secured
    NIH R01 renewal
    Transgenerational effects of cocaine self-administration on behavior
    $1.2M
  • 2015 - secured
    NIH R21
    Effect of cocaine intake and incubation on histone modification landscape
    $275k